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Summary Serial thyroid functions studies were carried out in patients with melanoma and renal cell
carcinoma treated with interleukin-2 (3 MU m-2 by continuous infusion days 1-4) and interferon a-2a
(6 MU m-2 subcutaneously on days 1 and 4), both given on alternate weeks. The results on eight patients who
completed at least three cycles of treatment are described. Four patients developed thyroid dysfunction with a
hyperthyroid phase of 2 weeks followed by a hypothyroid phase ranging from 12 to 24 weeks. Two patients
became clinically symptomatic and required treatment. Fine-needle aspirates of the thyroid were obtained in
three patients with thyroid dysfunction. The cytology revealed a mixed cellular infiltrate with lymphocytes and
histiocytes, and immonocytochemical staining showed strong HLA-DR expression of all thyrocytes, both
suggestive of an autoimmune thyroiditis. One patient with thyroiditis developed anti-thyroglobuline anti-
bodies, the serology of all other patients was normal. Patients with thyroid dysfunction tended to have higher
in vivo stimulated lytic activity of peripheral mononuclear blood cells and had significantly higher levels of
CD16 positive blood cells as compared to euthyroid patients. The possibility of autoimmune thyroiditis should
be anticipated in future trials combining interleukin-2 and interferon at-2a.
High doses of interleukin-2 (IL-2) with or without lympho-
kine-activated killer (LAK) cells have been demonstrated to
have antitumor activity in human melanoma and renal cell
carcinoma, although at the cost of considerable acute toxicity
(Rosenberg et al., 1987; Fisher et al., 1988; Dutcher et al.,
1989; Stahel et al., 1989). With the aim to increase the
response rate and/or to reduce the IL-2 dose and toxicity
without loss of efficacy alternative schedules of IL-2 in com-
bination with other biologicals are currently being explored,
including the combination of IL-2 and interferon (INF) a-2a.
The rationale for this combination in melanoma and renal
cell carcinoma is two-fold: (1) both IL-2 and INF a-2a have
been shown to have activity against these tumours when used
as single agents; and (2) in combination, these drugs have a
synergistic anti-tumour effect in animal models (Brunda et
al., 1986). Various schedules of IL-2/INF a-2a are being
examined by several groups of investigators. Our own ongo-
ing phase II study investigates the tolerance and efficacy of
IL-2, 3 MU m-2 by continuous infusion days 1-4 and INF
a-2a 6 MU m-2 subcutaneously on days I and 4, both given
on alternate weeks in patients with metastatic melanoma and
renal cell carcinoma.
Subacute thyroid dysfunction has been reported in patients
treated with IL-2 and LAK cells. In a series of 34 patients,
retrospective laboratory analysis revealed a transient hypo-
thyroid state in seven patients (Atkins et al., 1988). Because
of this observation all patients in our current IL-2/INF a-2a
study were prospectively evaluated for clinical and laboratory
evidence of thyroid dysfunction. Four of eight patients who
completed at least three cycles of treatment developed thy-
roid dysfunction. This report describes the thyroid function
studies, summarises the cytological findings of fine-needle
aspirates of the thyroid of three patients who developed
hypothyroidism and attempts to correlate these results with
the cellular immune modulatory effect of treatment measured
in peripheral blood mononuclear cells (PMNCs).
Material and methods
Patient characteristics
Eight patients with metastatic melanoma or renal cell car-
cinoma were treated with IL-2, 3 MU m-2 by continuous
infusion days 1-4 and INF a-2a, 6 MU m-2 subcutaneously
on days I and 4, both given on alternate weeks. IL-2 (Ro
23-6019) and INF a-2a (Ro-22-8181) were provided by F.
Hoffmann-La Roche (Basle, Switzerland). The protocol was
approved by the institutional review board and all patients
gave written informed consent. Tumour response was
assessed at 8 weeks after four cycles of treatment or earlier if
deemed necessary by the investigator. Patients with stable
disease or response were continued for nine more cycles or
up to disease progression or patients intolerance. The entry
criteria were a Karnofsky score of at least 80%, measurable
metastatic melanoma or renal cell carcinoma, no evidence of
brain metastasis, no significant alterations in organ functions,
no endocrine disorders, and negative HIV and hepatitis
serology. Patients were evaluated for side-effects daily during
the 4 days of treatment and once during the 10 days of
resting period. Up to the time of writing eight patients
received at least three complete cycles of treatment and are
included in this report.
Thyroidfunction studies
Serum thyrotropin (time resolved fluoroimmunoassay, Delfia
hTSH, Pharmacia, Diibendorf, Switzerland) and serum thy-
roxine (RIA-gnost T4, Behringwerke, AG, Marburg, FRG)
were measured before treatment, bi-weekly during treatment
and every 4 weeks after discontinuation of treatment.
Serological studies
Anti-thyroglobuline and anti-microsomal antibodies were
measured monthly during treatment by Synchron enzyme
linked immunosorbent assay (Elias, Freiburg, FRG) and
every 4-6 weeks after discontinuation of treatment. Normal
range was considered to be 0-350 IE ml-' with
350-500 U ml-' borderline and > 500 IE ml-X elevated.
Levels of anti-nuclear, anti-mitochondrial, anti-parietal and
anti-islet cell antibodies were measured by indirect
immunofluorescence (Kit from Zeus Scientifics Inc., Raritan,
NJ, USA, and DMD AG, Schaffhausen, Switzerland).
Cytological studies
Fine-needle aspirations were done in three patients with thy-
roid dysfunction using a 25-gauge needle and a 20 ml dis-
posable syringe in a Cameco-holder. The aspirated cells were
smeared directly onto glass slides, immediately fixed in Del-
aunay solution and subsequently stained by the Papanicolaou
technique. For immunocytochemical analysis stained smears
were further processed. Coverslips were removed in xylol and
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smears rehydrated in graded alcohols. Endogenous perox-
idase was blocked with methanol/H202 and slides incubated
with a 1:10 dilution of the monoclonal antibody LN 3 (Bio-
test Diagnostics, Dreireich, FRG) which is directed against a
non-polymorphic antigen of the HLA-DR (Ia) region. Stain-
ing was performed using the ABC method (Dakopatts, Cop-
enhagen, Denmark).
Immune modulatory parameters on peripheral blood
mononuclear cells
Phenotyping Fresh PMNCs were obtained from blood
drawn through a central venous line into heparinised Vacu-
tainer (Becton-Dickinson, Basle, Switzerland) glass tubes. A
Ficoll (Seromed, Fakola AG, Basle, Switzerland) centrifuga-
tion was performed, cells were washed twice in Hank's
balanced salt solution (HBSS), and resuspended 1 x 106
PMNCs ml-' in HBSS. Aliquots of 50 ftl were incubated for
30 min at room temperature in the dark with 5-20 of
monoclonal antibodies against the CD8, CD16, CD56, and
CD57 antigens labelled with fluorescein isothiocyanate or
phycoerythrin (Becton-Dickinson, Basle, Switzerland). After
washing the PMNCs were fixed with paraformaldehyde 0.5%
in Ultracount (Becton-Dickinson, Basle, Switzerland) result-
ing in a final volume of 200 ftl per assay. The direct
immunofluorescence analysis was done on a EPICS Profile
Analyser (Coulter Electronics, Instrumenten-gesellschaft,
Zurich, Switzerland).
Assessment of lytic activity Daudi and K562 cell lines were
used for the assessment of LAK and NK activity, respec-
tively. Target cells were labelled with 100 gsCi "1chromium per
106 cells (Amersham, Rahn AG, Zurich, Switzerland) accord-
ing to standard procedure. Some 10,000 target cells per well
were plated in a microtitre plate (Falcon, Inotech AG, Woh-
len, Switzerland) in 50 il of complete medium consisting
(CM) of RPMI 1640 (Flow Laboratories AG, Baar, Switzer-
land) supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 50jig ml-' streptomycin, 50 U ml-' penicillin, and
100 U ml-' recombinant IL-2 (F. Hoffmann-La Roche, Bas-
le, Switzerland). PMNCs were pre-incubated for 1 h (1 x 106
cells ml-' at 37°C, 5% C02) in CM.
Appropriate 1:2 dilutions of effector cells in 100 l, CM
were added to the target cells resulting in effector/target
ratios ranging from 1:40 to 1:1.25. Spontaneous and maximal
5'chromium release was obtained by the addition of 100ylI
cell free CM and 0.1 M hydrochloride respectively. Microtitre
plates were incubated for 4 h (at 37°C, 5% C02), the super-
natants harvested with a Skatron Harvester system (Tec-
nomara AG, Zurich, Switzerland) and counted (2 min per
probe) with a gamma-counter (LKB Clinigamma, Pharmacia
AG, Dubendorf, Switzerland). All tests were done in quad-
ruplicate. Specific tumour cell lysis was calculated according
to the formula:
(experimental c.p.m.-spont. c.p.m.)/
(max. c.p.m. - spont. c.p.m.) x 100
Lytic units (LU) per ml blood were calculated based on the
E/T ratio at the intercept of 20% specific lysis of 5,000 target
cells.
Results
Eight patients were treated with at least three full cycles of
IL-2 and INF x-2a. None of the patients had a history of
endocrine disorders. All had normal thyroid function tests
and normal levels ofanti-thyroglobuline and anti-microsomal
antibodies before treatment was started. Patient characteris-
tics, response to treatment, and results of thyroid function
studies are summarised in Table I. Four patients had normal
thyroid function during and after completion of treatment.
Four patients developed thyroid dysfunction.
The evolution of thyroid dysfunction followed a similar
pattern in all four patients with laboratory evidence ofhyper-
thyroidism during the second or third cycle of treatment in
two patients each, followed by laboratory evidence of hypo-
thyroidism within 2 weeks. The changes in TSH and T4
levels over time for patient 3/M 1944, which are represen-
tative of all four patients with thyroid dysfunction, are de-
picted in Figure 1.
In patients 1 and 2 there was no clinical evidence for
thyroid dysfunction and thyroid function studies returned to
normal within 10-22 weeks after discontinuation of IL-2/
INF a-2a therapy. Patients 3 and 4 became clinically symp-
tomatic with tachycardia of up to 150 beats min-' requiring
therapy with a P-blocker. This was followed by an inapprop-
riate degree of fatigue in both and the development of a
unilateral carpal tunnel syndrome in patient 4. Both were
substituted with sodium L-thyroxine 0.5-1.0 mg daily for 11
and 18 weeks.
In one patient with hypothyroidism anti-thyroglobuline
antibodies became elevated from 32 IU ml1' at baseline to a
maximum of 1,236 IU ml-' at week 5. They returned to
normal within 6 months. In all other patients anti-
thyroglobuline and anti-microsomal antibodies remained at
normal values. No other autoantibodies, including anti-mito-
chondrial, anti-nuclear, anti-parietal cell or anti-beta islet cell
antibodies were detected.
No patient had clinically detectable thyroid enlargement.
Patients 2, 3 and 4 underwent fine-needle aspirations of the
thyroid during the third or fourth cycle of treatment. All
three had cytological evidence of chronic thyroiditis mani-
fested in a mixture of lymphocytes, plasma cells, histiocytes
and thyroid epithelial cells (Figure 2). The fine-needle as-
pirates of the three patients and of three untreated controls
were examined for expression of class II antigens by immuno-
cytochemistry. Thyroid epithelial cells of all three patients
revealed strong expression of HLA-DR antigen (Figure 3a),
while controls remained antigen negative (Figure 3b). Patient
I had a subclinical course which was detected only later
during treatment and therefore had no biopsy done.
Functional NK and LAK activity of PNMCs and the
number of PMNCs with NK markers were determined at
baseline and after stimulation at day 8 of the third
Table I Patient characteristics
Number Response
sex after Antithyroid L-Thyroxin date ofbirth Tumour 4 cycles TSHmaxa TSHmina T4maxb T4minb antibodiesc FNA replacement
1/M/1944 RCC PD 22.7 <0.08 165 64 not elevated no no 2/F/1940 MM MR 2 <0.08 197 56 not elevated yes no 3/M/1944 MM PD 61.4 <0.08 218 32 1236 IEml- yes yes 4/F/1946 MM MR 63 <0.08 192 5 not elevated yes yes
5/F/1929 MM PD 3.5 1.8 132 92 not elevated no no 6/M/1930 RCC NC 1.2 0.4 147 70 not elevated no no 7/F/1940 RCC PD 1.5 0.5 98 72 not elevated no no 8/M/1930 RCC PD 2.5 1.6 102 62 not elevated no no
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Figure 1 Serum thyroxine and thyrotropin concentration of pa-
tient 3/M/1944 with autoimmune thyroiditis in relation to treat-
ment with IL-2 and INF a-2a.
Figure 2 Papanicolaou stain of fine needle aspirate of the thy-
roid from patient 3/M/1944, showing chronic inflammation with
lymphocytes, plasmacells and histiocytes. Original magnification
x 330.
cycle of treatment. Mean baseline NK and LAK activity was
117 LU ml-' and 6.7 LU ml-, respectively and increased to
385 LU ml1' and 98 LU ml-', respectively on day 8 of cycle
3. Baseline CD16 positive cells were 0.25 g I-' and increased
to 1.05 g 1' on day 8 of cycle 3. Figure 4 compares these
immune modulatory parameters in patients with and without
thyroid dysfunction. Patients with thyroid dysfunction tended
to have a higher stimulated NK activity and LAK activity
than euthyroid patients. The number of CD16 positive cells
at baseline and after stimulation was significantly higher in
patients with thyroid dysfunction. No significant differences
were found in the absolute number of lymphocytes and the
number of CD8, CD56 and CD57 positive cells.
Discussion
Our observations suggest that transient thyroid dysfunction
is a common finding with combined IL-2/INF a-2a therapy.
In our series of eight and a similar series of seven patients
from another center (communicated by Pichert et al., 1989)
half of the patients treated for melanoma and renal cell
carcinoma were found to have thyroid dysfunction, a much
higher frequency than with IL-2 and LAK cell therapy,
where it has been reported in seven of 34 (21%) patients
treated for melanoma, renal cell carcinoma or colon car-
cinoma (Atkins et al., 1988), or with human leukocyte inter-
feron therapy, where it has been reported in seven of 49
(14%) patients treated for carcinoid (Burman et al., 1986)
Figure 3 a, Immunocytochemistry of fine needle aspirate of
patient 3/M/1944 showing strong HLA-DR expression on thyroid
epithelial cells. Original magnification x 528. b, Immunocyto-
chemistry of fine needle aspirate of a normal thyroid as control,
showing negative staining for HLA-DR. Original magnification
x 528.
and three of 13 (23%) patients treated for breast cancer
(Fentimann et al., 1988).
The thyroid dysfunction observed in our study is caused by
an autoimmune thyroiditis, as evidenced by the evolution of
thyroid function studies, the cellular infiltrates in fine-needle
aspirates and by the expression of HLA class II antigens by
thyroid epithelial cells. This condition evolved within 4-6
weeks of alternate weekly IL-2/INF x-2a therapy with first a
hyperthyroid phase of 2 weeks duration followed by a
hypothyroid phase lasting up to 24 weeks. Three patients had
a fine-needle aspirate of the thyroid during the hypothyroid
state and all three showed a pattern consistent with an
autoimmune thyroiditis with a mixed lymphocytic/histiocytic
infiltrate and strong staining of thyrocytes for HLA class II
antigens. In contrast to Hashimoto's thyroiditis which is
usually long lasting and often evolves into a permanent
hypothyroid state (Doniach et al., 1979), the thyroiditis ob-
served in our patients was self-limited.
Bottazzo et al. (1983) initially suggested aberrant HLA
class II expression on thyrocytes as a key factor for the
induction of autoimmune thyroiditis. Normal thyrocytes do
not express HLA class II antigens, whereas strong expression
has been demonstrated in patients with autoimmune thyroid-
itis (Hanafusa et al., 1983). In vitro, HLA class II expression
can be induced on cultured human thyrocytes by adding
activated T-cells or more directly recombinant INF -, (Todd
et al., 1985). TNF a enhances the effect of INF y (Buscema et
al., 1989); recombinant IL-2 (Todd et al., 1985) or INF a
(Burman et al., 1986) added in the absence of INF y fail to
induce HLA class II on human thyrocytes.
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Figure 4 Immunomodulatory effect of IL-2/INF a-2a in four
patients with thyroiditis (@) and four patients without thyroiditis
(0). Mean values and standard deviation at study entry and at
day 8 of cycle 3. a, NK activity of PMNCs against K562 target
cells. b, LAK activity of PMNCs against Daudi target cells. c,
Circulating CD8-positive cells. d, Circulating CD16-positive cells.
In thyroid glands of patients with Hashimoto's thyroiditis
or Graves' disease the highest epithelial expression of HLA-
DR antigen was found in areas of most intense lymphoid
infiltrates (Flynn et al., 1988). Therefore it is possible that
HLA-DR expression is induced as a result of intercellular
communication of activated lymphocytes and macrophages
with thyroid epithelial cells; a process which involves cyto-
kines and which results in an inappropriate antigen recogni-
tion of thyrocytes by autoagressive T cell clones. In addition
to INF y and TNF aother cytokines may be involved such
as interleukin-l which has been found to affect directly the
function of thyrocytes in vitro (Rasmussen et al., 1987).
With the exception of two case reports treated with IL-2
(van Liessum et al., 1989; Hartmann et al., 1989), hypo-
thyroidism has not been observed with the use of IL-2 or
INF a-2a alone. We suggest that the high frequency of
thyroiditis observed with IL-2/INF a-2a treatment is based
on several factors. (1) The combined treatment with IL-2 and
INF a-2a may lead to a pronounced secretion of secondary
cytokines including INF ', TNF a and IL-I (Gemlo et al.,
1988; del Prete et al., 1987). Whereas INF y and TNFa have
also been detected in the serum of patients after IL-2 alone
the titers are more impressive after treatment with IL-2 and
LAK cells (Gemlo et al., 1988), which comprise well estab-
lished sources of cytokines such as IL-1, TNF a and INF T.
(2) The development of thyroiditis may also depend on a
more pronounced recruitment of autoreactive T cell clones or
a hyperinduction of the cytolytic potential of mononuclear
cells by IL-2 and INF a and not with either agent alone. In
the mouse model it has been shown, that the frequency of
lytic effector cells in the liver is significantly greater with the
combination than with IL-2 or INF a-2a alone (Brunda et
al., 1986). Furthermore, in patients with Hashimoto's thy-
roiditis the proportion of INF "y producing T cell clones
derived from thyroid infiltrates was significantly higher than
in the peripheral blood of healthy donors and there was a
positive relationship between high INF y production and NK
activity of T cell clones of peripheral blood and thyroid
glands of patients with Hashimoto's disease (del Prete et al.,
1987). In this regard it is of note that in our small series
patients with thyroiditis tended to have a higher lytic poten-
tial of peripheral blood mononuclear cells and a significantly
higher number of CD16 positive PMNCs than patients with-
out thyroiditis.
It is pertinent to ask why autoimmune disease has been
restricted to the thyroid and why only selected patients were
afflicted. In general there appears to be a genetic basis for the
tendency to develop autoimmunity as evidenced by HLA
associations and family studies which are also indicative for a
preference for a particular organ (Flynn et al., 1988). In
experimental models a restricted usage of some T cell recep-
tor VP3 genes in the T cell response to defined determinants
on autoantigens had been shown (Zamvil et al., 1988). An
individual disease susceptibility has been suggested by the
observation of genetic differences in the amount of MHC
class II expression following IFN y treatment of parenchymal
cells (Massa et al., 1987).
HLA class II antigen expression on tumour cells has been
found associated with responsiveness to IL-2 and LAK cell
therapy and an association between hypothyroidism and
tumour response to IL-2 and LAK cells has been suggested
(Cohen et al., 1987). This hypothesis is also supported by our
preliminary observations together with a group of inves-
tigators in Dublin with four tumour responses to IL-2/INF
a-2a treatment (two minor and two partial) in eight patients
with hypothyroidism, and no responses in seven euthyroid
patients (communicated by Pichert et al., 1989). Together
these observations suggest that the expression of HLA class
II antigens and auto-reactive cytotoxic T-lymphocytes might
contribute to the development of thyroiditis as well as to the
anti-tumour response, in addition to NK and LAK cells
which act independent of the HLA class II system.
Self-limited thyroiditis with hyperthyroidism followed by
hypothyroidism occurs in half of the patients treated with
IL-2 and INF a-2a. Clinical or laboratory thyroid dysfunc-
tion should be anticipated in future clinical trials with these
substances. Also the possibility of a positive correlation
between tumour response and the occurrence of thyroiditis
needs further evaluation.
We thank Prof. A. Fontana for helpful discussion.
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